Imatinib: A review of its use in the management of gastrointestinal stromal tumours

Drugs

Volumn 67, Issue 5, 2007, Pages 805-820

  Siddiqui, M Asif A ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERICUM PERFORATUM EXTRACT; IMATINIB; KETOCONAZOLE; PARACETAMOL; RIFAMPICIN; SIMVASTATIN; SUNITINIB;

ABDOMINAL PAIN; ANEMIA; AREA UNDER THE CURVE; BLEEDING; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FLUID RETENTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENOTYPE; GRANULOCYTOPENIA; HEMATOLOGIC DISEASE; HUMAN; HYPOPHOSPHATEMIA; INFECTION; KIDNEY DISEASE; LEUKOPENIA; LIVER TOXICITY; NAUSEA; NONHUMAN; PLEURAL PAIN; PROGNOSIS; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; VOMITING;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 34047192180     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767050-00012     Document Type: Review

References (73)

1. Sabah M, Leader M, Kay E. Gastrointestinal stromal tumours: an update. Curr Diagn Pathol 2005; 11 (6): 400-10
2. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005 Apr; 16 (4): 566-78
3. van der Zwan SM, Dematteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer 2005 Nov; 104 (9): 1781-8
4. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22 (18): 3813-25
5. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001 Nov; 61 (22): 8118-21
6. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005 Aug 10; 23 (23): 5357-64
7. Shinomura Y, Kinoshita H, Tsutsui S, et al. Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors. J Gastroenterol 2005; 40: 775-80
8. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003 Dec 1; 21 (23): 4342-9
9. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003 Jan 31; 299 (5607): 708-10
10. Moen MD, McKeage K, Plosker GL, et al. Imatinib: a review of its use in chronic myeloid leukaemia. Drugs 2007; 67 (2): 299-320
11. Curran MP, Croom KF, Goa KL. Imatinib mesylate: a review of its use in chronic myeloid leukemia. Am J Cancer 2003; 2 (6): 439-54
12. Lyseng-Williamson K, Jarvis B. Imatinib. Drugs 2001; 61 (12): 1765-74; discussion 1775-6
13. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001 Apr 5; 344 (14): 1052-6
14. Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs 2003; 63 (5): 513-22
15. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44 (9): 879-94
16. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295 (1): 139-45
17. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001 Aug 16; 20 (36): 5054-8
18. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96 (3): 925-32
19. Prenen H, Deroose C, Vermaelen P, et al. Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography. Anticancer Res 2006 Mar 30; 26 (2A): 1247-52
20. Bono P, Krause A, von Mehren M, et al. Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood 2004 Apr 15; 103 (8): 2929-35
21. Ermer A, Huber V, Gilch S, et al. The anticancer drug imatinib induces cellular autophagy. Leukemia 2007 Mar 1 [Epub ahead of print]
22. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002 Aug 15; 347 (7): 472-80
23. Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005 Aug 20; 23 (24): 5795-804
24. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364 (9440): 1127-34
25. Fletcher JA, Corless CL, Dimitrijevic S, et al. Mechanisms of resistance to imatinib mesylate in advanced gastrointestinal stromal tumor [Abstract no. 3275]. Proc Am Soc Clin Oncol 2003; 22: 815
26. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005 Feb 1; 128 (2): 270-9
27. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006 Oct 10; 24 (29): 4764-74
28. Thomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004 Dec 1; 104 (12): 3739-45
29. Judson I, Ma P, Peng B, et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 2005 Apr; 55 (4): 379-86
30. Burger H, Nooter K. Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. Cell Cycle 2004 Dec; 3 (12): 1502-5
31. Hamada A, Miyano H, Watanabe H, et al. Interaction of imatinib mesilate with human p-glycoprotein. J Pharmacol Exp Ther 2003; 307 (2): 824-8
32. Delbaldo C, Chatelut E, Re M, et al. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 2006 Oct 15; 12 (20 Pt 1): 6073-8
33. Committee for Proprietary Medicinal Products. European public assessment report on Glivec (revision 1): scientific discussion. London: European Agency for the Evaluation of Medicinal Products, 2002; CPMP/2418/01
34. Novartis Pharmaceuticals Corporation. Product information (US): Gleevec® (imatinib mesylate) tablets 100 and 400mg [online]. Available from URL: http://www.fda.gov/cder [Accessed 2007 Jan 22]
35. Novartis Europharm Limited. Product information (EU): Glivec® (imatinib mesylate) tablets 100 and 400mg [online]. Available from URL: http://www.emea.eu.int/ [Accessed 2007 Jan 22]
36. Glivec® GIST clinical monograph. Basel: Novartis Pharma AG, 2002
37. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004 Mar; 22 (5): 935-42
38. Peng B, Dutreix C, Mehring G, et al. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 2004 Feb; 44 (2): 158-62
39. Gschwind HP, Pfaar U, Waldmeier F, et al. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 2005 Oct; 33 (10): 1503-12
40. Dutreix C, Peng B, Mehring G, et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 2004 Oct; 54 (4): 290-4
41. Frye RF, Fitzgerald SM, Lagattuta TF, et al. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004 Oct; 76 (4): 323-9
42. Bolton AE, Peng B, Hubert M, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004 Feb; 53 (2): 102-6
43. O'Brien SG, Meinhardt P, Bond E, et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 2003 Nov 17; 89 (10): 1855-9
44. Rankin C, Von Mehren M, Blanke C, et al. Dose effect of imatinib in patients with metastatic GIST: phase III Sarcoma Group Study S0033 [abstract no. 9005 plus oral presentation]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans (LA)
45. Blanke CD, Joensuu H, Demetri GD, et al. Outcome of advanced gastrointestinal stromal tumor patients treated with imatinib mesylate: four-year follow-up of a phase II randomized trial [Abstract no. 7 plus oral presentation]. The American Society of Clinical Oncology 3rd Annual Gastrointestinal Cancers Symposium; 2006 Jan 26-28; San Francisco (CA)
46. van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumours: a report of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2002; 38 Suppl. 5: S83-7
47. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003 Sep; 39 (14): 2006-11
48. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239-53
49. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92 (3): 205-16
50. Blanke CD, Demetri GD, Von Mehren M, et al. Efficacy of imatinib mesylate in advanced gastrointestinal stromal tumor (GIST) patients (pts) according to tumor bulk. [abstract no. 21]. The American Society of Clinical Oncology 4th Annual Gastrointestinal Cancers Symposium; 2007 Jan 19-21; Orlando (FL)
51. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005 Aug; 41 (12): 1751-7
52. Le Cesne A, Ray-Coquard I, Bui B, et al. Interruption of imatinib in responding patients after one year treatment does not influence overall survival of patients with advanced GIST: updated results of the French Sarcoma Group randomized phase III BFR14 trial. Eur J Cancer Suppl 2005 Oct; 3 (2): 202
53. Blay JY, Berthaud P, Perol D, et al. Continuous vs intermittent imatinib treatment in advanced GIST after one year: a prospective randomized phase III trial of the French Sarcoma Group. [Abstract no. 9006 plus oral presentation]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans (LA)
54. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004 Mar; 40 (5): 689-95
55. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006 May; 42 (8): 1093-103
56. Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006 Aug; 12 (8): 908-16
57. Force T. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' [letter]. Nat Med 2007 Jan; 13 (1): 15-6
58. Hatfield A, Owen S, Pilot PR. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 2007 Jan; 13 (1): 13
59. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006 May 11; 354 (19): 2006-13
60. National Comprehensive Cancer Network (NCCN) soft tissue sarcoma panel. NCCN clinical practice guidelines in oncology: soft tissue sarcoma (version 3.2006) [online]. Available from URL: http://www.nccn.org [Accessed 2007 Jan 22]
61. Blanke C, Eisenberg BL, Heinrich M. Epidemiology of GIST [letter]. Am J Gastroenterol 2005 Oct; 100 (10): 2366
62. Goettsch WG, Bos SD, Breekveldt-Postma N, et al. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer 2005 Dec; 41 (18): 2868-72
63. DeMatteo RP, Lewis J, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231 (1): 51-8
64. Blackstein ME, Blay JY, Corless C, et al. Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Can J Gastroenterol 2006 Mar; 20 (3): 157-63
65. Dileo P, Rankin CJ, Benjamin RS, et al. Incidence and reasons for dose modification of standard-dose vs high-dose imatinib mesylate in the phase III intergroup study S0033 of patients with unresectable or metastatic gastrointestinal stromal tumor [abstract no. 9032]. J Clin Oncol 2005 Jun; 23 Suppl. 16S Pt 1: 824. Plus oral presentation made at the 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13-17; Orlando (FL)
66. Scaife CL, Hunt KK, Patel SR, et al. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 2003 Dec; 186 (6): 665-9
67. GIST Support International. Current trials [online]. Available from URL: http://www.gistsupport.org/ [Accessed 2006 Aug 23]
68. Blackstein ME, Rankin C, Fletcher C, et al. Clinical benefit of imatinib in patients with metastatic gastrointestinal stromal tumors negative for the expression of CD117 in the SOO33 trial [abstract no. 9010]. J Clin Oncol 2005 Jun; 23 Suppl. 16S Pt 1: 818
69. Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004 Jul; 28 (7): 889-94
70. Huse DM, von Mehren M, Lenhart G, et al. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors. Clin Drug Invest 2007; 27 (2): 85-93
71. Huse D, Finkelstein S, Glendenning A, et al. Cost-effectiveness of imatinib in the treatment of gastrointestinal stromal tumors [abstract no. MO-1800-1900-40.144-2]. 5th World Congress of the International Health Economics Association; 2005 Jul 9-13; Barcelona
72. Finketstein SN, Huse DM, Glendenning GA, et al. Imatinib: cost-effective in the treatment of gastrointestinal stromal tumors [abstract no. 762P]. Ann Oncol 2004; 15 Suppl. 3: 201
73. De Abreu Lourenco R, Wonder M. The cost effectiveness of imatinib for the treatment of patients with gastrointestinal stromal tumours [abstract no. PCSC3]. 1st Asia-Pacific meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2003 Sep 1-3; Kobe